Phase 3 randomized study of adjuvant anastrozole (A), exemestane (E) or letrozole (L) with or without tamoxifen (T) in postmenopausal women with hormone-responsive (HR) breast cancer. The FATA-GIM3 trial

S. De Placido, C. Gallo, M. De Laurentiis, G. Bisagni, G. Arpino, M. G. Sarobba, F. Riccardi, A. Russo, L. Del Mastro, A. Cogoni, F. Cognetti, S. Gori, A. Frassoldati, D. Amoroso, L. Laudadio, L. Moscetti, F. Montemurro, F. Nuzzo, P. Carlini, F. Perrone

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)vi1
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Publication statusPublished - Oct 1 2017

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this